文献速递湿疹皮炎与荨麻疹

Tapinarof 1%乳膏每日一次治疗中重度特应性皮炎:3期ADORING试验显著有效

Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.
PubMed 文献 · J Am Acad Dermatol · 2024-05-20

第8周IGA 0/1且改善≥2级比例分别为45.4% vs 13.9%和46.4% vs 18.0%,EASI75为55.8% vs 22.9%和59.1% vs 21.2%(均P<.0001),瘙痒快速改善且安全性良好。

要点

  • Tapinarof 1%每日一次在第8周IGA成功率显著优于赋形剂。
  • EASI75应答率约55.8%–59.1%,显著高于赋形剂。
  • 常见不良事件为毛囊炎、头痛、鼻咽炎,多为轻中度。

核心结论

  • Tapinarof 1%乳膏每日一次对2岁及以上特应性皮炎患者显示高度显著疗效和良好安全性。

主要发现

  • 第8周IGA 0/1且改善≥2级比例:45.4% vs 13.9%和46.4% vs 18.0%(均P<.0001)。
  • 第8周EASI75比例:55.8% vs 22.9%和59.1% vs 21.2%(均P<.0001)。
  • 患者报告瘙痒快速改善显著优于赋形剂。
  • 常见不良事件(≥5%)为毛囊炎、头痛、鼻咽炎,多为轻中度,因不良事件停药率低于赋形剂组。

临床怎么用

  • 可考虑将Tapinarof 1%每日一次作为2岁及以上中重度特应性皮炎的局部治疗选择。

局限性

  • 未评估长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tapinarof cream 1% once daily (QD), a topical aryl hydrocarbon receptor agonist, downregulates pro-inflammatory Th2 cytokines, upregulates skin-barrier components, and reduces oxidative stress. OBJECTIVE: To assess tapinarof efficacy and safety in adults and children down to 2 years of age with atopic dermatitis (AD). METHODS: Eight hundred and thirteen patients were randomized to tapinarof or vehicle QD in two 8-week phase 3 trials. RESULTS: The primary efficacy endpoint, Validated Investigator Global Assessment for Atopic Dermatitis score of 0 or 1 and ≥2-grade improvement from baseline at Week 8, was met with statistical significance in both trials: 45.4% versus 13.9% and 46.4% versus 18.0% (tapinarof vs vehicle; both P < .0001). Significantly superior Eczema Area and Severity Index 75 (EASI75) responses were also observed with tapinarof versus vehicle at Week 8: 55.8% versus 22.9% and 59.1% versus 21.2% (both P < .0001). Rapid improvements in patient-reported pruritus were also significant with tapinarof versus vehicle. Common adverse events (≥5%) of folliculitis, headache, and nasopharyngitis were mostly mild or moderate, with lower discontinuations due to adverse events in the tapinarof groups than with vehicle. LIMITATIONS: Long-term efficacy was not assessed. CONCLUSION: Tapinarof demonstrated highly significant efficacy and favorable safety and tolerability in a diverse population of patients with AD down to 2 years of age.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024. PMID: 38777187. doi:10.1016/j.jaad.2024.05.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。